Innoviva (NASDAQ: INVA)
Innoviva Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Innoviva Company Info
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
News & Analysis
3 Small-Cap Stocks With Big-Cap Potential
These stocks are just temporarily inconvenienced large caps in the making.
2 Best Biotech Stocks to Buy in August
These two stocks are probably undervalued, but that won’t last forever.
2 Incredibly Cheap Biotech Stocks
These promising stocks have been flying under the radar this year, but they're worth another look.
3 Top Biotech Stocks to Buy in April
These three biotech stocks are worth buying this month.
3 Under-the-Radar Value Stocks to Buy in 2019
These might be the cheapest stocks you've never heard about.
13 of the Cheapest Healthcare Stocks
Each of these stocks has a PEG ratio below 1, but that doesn't make them all worth buying.
3 Top Healthcare Stocks to Buy in June
These three mid-cap healthcare stocks could be your prescription for profits.
The Cheapest Drug Stocks to Buy Right Now
All three of these bargains have forward P/E ratios of less than eight.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.